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ABSTRACT
For two decades the scientiﬁc community has sought to
understand why some people clear hepatitis C virus
(HCV) and others do not. Recently, several large
genome-wide association studies have identiﬁed single
nucleotide polymorphisms (SNPs) linked to interferon
lambda 3 (IFNl3) that are associated with the
spontaneous resolution and successful treatment of HCV
infection. These observations are generating intense
research activity; the hope is that IFNl3 genetic variants
may serve as important predictive biomarkers of
treatment outcome and offer new insights into the
biological pathways involved in viral control. A
pharmacogenomic treatment approach for HCV can now
be envisaged, with the incorporation of host genetic
variants into a predictive treatment algorithm with other
factors. The SNPs associated with the clinical outcome
of HCV infection are located some distance from the
IFNl3 gene itself, and causal genetic variants have yet
to be clearly deﬁned. Locating these causal variants,
mapping in detail the IFNl3 signalling pathways and
determining the downstream genetic signature so
induced will clarify the role of IFNl3 in the pathogenesis
of HCV. Clinical studies assessing safety and efﬁcacy in
the treatment of HCV with exogenous IFNl3 are
currently underway. Early results suggest that IFNl3
treatment inhibits HCV replication and is associated with
a limited side effect proﬁle. However, hepatotoxicity in
both healthy volunteers and HCV-infected patients has
been described. This review discusses the genetic
studies that link IFNl3 to both the spontaneous
resolution and treatment-induced clearance of HCV and
the potential impact of this in clinical practice, the
biology of IFNl3 as currently understood and how this
may impact on HCV infection, and describes the early
studies that assess the role of this cytokine in the
treatment of patients with HCV.
INTRODUCTION
For more than two decades, interferon-a (IFNa)
treatment has formed the cornerstone of therapy
for hepatitis C virus (HCV) infection. Despite the
identiﬁcation of some viral and host factors asso-
ciated with viral clearance, response to therapy
remains highly unpredictable. Since treatment
is prolonged, expensive and fraught with side
effects, intense efforts have been made to identify
biomarkers predictive of a successful treatment
outcome. In 2009 there was a major breakthrough
in this endeavour with the discovery that single
nucleotide polymorphisms (SNPs) linked to
the cytokine IFNl3 (also known as IL28B) are
a dominant host factor at a population level in
determining treatment outcome. Furthermore, the
same SNPs are associated with the clinical outcome
of primary infectiondan intense area of research in
the ﬁeld of HCV over recent years. It is therefore
not surprising that IFNl is creating a storm in the
HCV arena.
This review describes the discovery of IFNl3-
linked SNPs that are associated with HCV control,
summarises the biology and function of IFNl3a s
currently understood and describes the early studies
that assess the role of this cytokine in the treat-
ment of patients.
Identiﬁcation of IFNl3 as a key cytokine in HCV
infection using genetic technology
Over the last decade a number of host factors have
been shown to play a role in the clinical outcome of
HCV using either a candidate gene approach or
through the assessment of biological pathways or
demographic features that have an expected role in
infection control. For example, in acute infection,
particular human leucocyte antigens (both HLA
classes I and II) and robust T cell immunity have
been associated with viral clearance.
1e3 Single-
source HCV outbreak studies most clearly demon-
strate the importance of host factors in response to
HCV infection.
4 In these studies, young women
were infected with the same inoculum of HCV
from contaminated anti-D immunoglobulin.
Approximately half of the women developed
persistent infection while the remainder cleared the
virus spontaneously, showing that host factors are
important in determining clinical outcome. Simi-
larly, in the treatment of persistent HCV infection,
some host factors such as male gender and African
ethnicity are associated with a poor treatment
outcome.
5e7 However, the actual predictive value
of these factors is low, suggesting that other
factors, hitherto unidentiﬁed, must exist. These
observations provided the rationale for fully
assessing the contribution of the host genome to
the outcome of HCV infection.
The development of the human HapMap project
in 2002 (http://hapmap.ncbi.nlm.nih.gov/) and
advances in genetic techniques that facilitate the
analysis of large datasets has led to an exponential
growth in genome-wide association studies
(GWAS). These studies associate common SNPs
throughout the host genome with a disease cohort,
and so identify important biological pathways in
disease without prior knowledge or prejudice as to
their relevance. This technique contrasts with
candidate gene studies that take a pre-identiﬁed
relevant gene and speciﬁcally assess its prevalence
in the target population. The polarised clinical
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Recent advances in basic scienceoutcome of HCV infection (that of viral clearance
versus viral persistence) makes HCV infection an
ideal candidate for a GWAS approach.
The ﬁrst GWAS in HCV infection was published
by Ge and colleagues in September 2009.
8 This study
assessed the treatment outcome in a group of 1671
patients of mixed ethnicity (American European,
Hispanic and African) receiving pegylated-IFNa
(PEG- IFNa) and ribavirin. A striking association
was discovered between sustained viral response
(SVR) with treatment and a cluster of seven SNPs
linked to the IL28B gene, with the most signiﬁcant
SNP (rs12979860) demonstrating extremely high
statistical signiﬁcance (p¼1.06310
-25). No SNPs
linked to other genes were associated with treat-
ment outcome at genome-wide signiﬁcance. Patients
homozygous for the protective allele (C/C) had an
SVR rate that was approximately three times higher
than homozygotes for the risk allele (T/T) (78% vs
28%), and simply being a heterozygote carrier (T/C)
for the risk allele also demonstrated approximately
a twofold decrease in SVR (38%) compared with
those homozygous for the protective allele,
suggesting a dominant role for the risk SNP. In
assessing other factors linked to viral clearance, host
IFNl3 genotype was more important than baseline
viral load, the degree of liver ﬁbrosis or ethnicity
(ﬁgure 1).
Many other studies have since replicated these
ﬁndings, demonstrating the robust association
between IFNl3 and treatment outcome in other
populations including Japanese, Australian, Euro-
pean, African American and Hispanic using either
a GWAS approach
8e11 or a candidate gene approach
(table 1, ﬁgures 2 and 3).
12e18
Shortly after the landmark publication by Ge
et al,
8 the same gene (using a candidate gene
approach assessing SNP 12979860) was shown to
play a key role in the spontaneous resolution of
disease following primary infection in both African
and Caucasian populations.
18 This study showed
that carriers of the risk allele were three times less
likely to spontaneously clear the virus than
homozygotes for the protective allele. This ﬁnding
was subsequently supported in a large GWAS by
Figure 1 Odds ratio (OR) of treatment failure in hepatitis C virus (HCV) infection. OR of
risk factors associated with treatment failure including the interferon l3 (IFNl3)-linked
single nucleotide polymorphisms (rs8099917, rs12979860, rs12980275) in published
genome-wide association studies.
8e11 *Derived from Rauch et al.
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Recent advances in basic scienceRauch et al
9 in both HCV-infected patients and
HIVand HCV co-infected patients. It is now quite
clear that the IFNl pathway plays a key role in
natural host immunity as well as in the response to
IFNa treatment of HCV infection.
Although the SNPs identiﬁed in the ﬁrst phase of
the GWAS above are linked to the IFNl3 gene, they
are not located within known regulatory elements
or the coding region of the IFNl3 gene itself.
Rather, they have an expected association with
‘functional’ polymorphisms involved in the regula-
tion or the function of the IFNl3 gene product.
This is because IFNl3 has a distinct haplotype
block (distinct regions of the host genome with
SNPs that are in tight linkage disequilibrium with
one another) that extends beyond the gene and the
gene regulatory elements. The most signiﬁcantly
associated SNP identiﬁed by Ge and colleagues
(rs12979860) lies 3 kb upstream of the IFNl3 gene.
8
In an attempt to identify the functional (or causal)
polymorphism, these authors sequenced the IFNl3
gene itself in 96 individuals and found two variants
(one 37 base pairs upstream of the translation
initiation codon (rs28416813) and a non-synony-
mous coding SNP (rs8103142) encoding an amino
acid substitution within the IFNl3 gene. However,
these variants were so tightly linked that further
genotyping of the entire cohort failed to show that
any of these SNPs were uniquely linked to treat-
ment outcome. Several studies have identiﬁed SNP
rs8099917 as that most signiﬁcantly associated
with outcome.
9e11 This SNP is located 8.9 kb from
the end of transcription of IFNl3 in the intergenic
region between IFNl2 and IFNl3. Suppiah and
colleagues further clariﬁed the association and
genotyped 20 SNPs in the IFNl3, IFNl2, IFNl1
gene cluster region.
10 Haplotype analysis identiﬁed
a six-allele haplotype that was tagged by rs809917
(rs12980275, rs8105790, rs8103142, rs10853727,
rs8109886 and rs8099917) linked to SVR. Notably,
this haplotype encompasses regulatory elements
from both IFNl3 and IFNl2. Tanaka and colleagues
also sequenced 48 patients and established a similar
seven-allele haplotype (rs8105790, rs11881222,
rs8103142, rs28416813, rs4803219, rs8099917 and
rs7248668) associated with SVR (OR 11.1
(p¼1.35310
-25, 95% CI 6.6 to 18.6).
11 Similarly,
Rauch and colleagues, in searching for the causal
variants, resequenced the IL28B locus in 47 indi-
viduals with and without the SNP rs8099917 and
with different treatment outcomes and identiﬁed
21 SNPs, of which ﬁve tightly linked SNPs were
thought to be potentially causative.
9
Since multiple tightly-linked SNPs within and
around the IFNl3 gene are associated with SVR, it
seems unlikely that sequence studies of the IFNl3
region in association with known clinical outcome
will identify which of these are causal. In vitro
IFNl3 functional assays combined with mutagen-
esis studies will determine the effect of these
polymorphisms on IFNl3 function, although even
these may not prove causality. A further note of
caution: while it is generally assumed that common
variants associated with disease in GWAS reﬂect
the effect of a causal variant in close proximity, this
is not necessarily so. Rare causal variants cannot be
detected using GWAS technology, which only
screens the human genome for common SNPs. An
alternative possibility, therefore, is that multiple
rare variants that lie distant from the common
variant identiﬁed in GWAS occur stochastically and
more frequently in association with the GWAS
common variant. These associations have been
termed ‘synthetic’.
19 In this scenario a common
variant identiﬁed in the GWAS will be erroneously
linked to a disease due to its chance association
with the true causal variants which lie undetected
by GWAS methodology. This possibility has been
demonstrated by the analysis of existing datasets
Figure 2 Interferonl3 (IFNl3) risk allele frequency in speciﬁc populations infected with
hepatitis C virus (HCV). Risk allele frequency in those who clear acute infection
spontaneously and in those who have a successful treatment response (SVR) compared
with individuals who develop persistent infection or who fail treatment (non-SVR).
8e11 18
Figure 3 Mean frequency of interferon l3 (IFNl3)
protective allele in different ethnic groups. The protective
allele is less common in African populations than in Asian
populations, correlating with the known poor outcome
from hepatitis C virus (HCV) infection in patients of
African origin. Figure derived from data in Thomas et al.
18
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Recent advances in basic scienceshowing that known rare causal mutations
responsible for sickle cell disease and hearing loss
can give rise to genome-wide signiﬁcant synthetic
associations that lie a considerable distance
(2.5 Mb) from the causal mutations.
20 These
observations do not detract from the use of the
GWAS variants in predicting treatment outcome in
HCV infection, but they do raise the possibility
that the biological mechanisms that underpin this
are related to distant multiple rare genetic variants.
It has been known for some time that ethnicity
affects treatment outcome of HCV infection, with
viral clearance rates lowest in African-Americans,
highest in East Asians and intermediate in Euro-
pean-Americans.
5e7 We now know that the
underlying rate of carriage of the IFNl3 risk allele
depends on the ethnic group of the population
under study (ﬁgure 3). This suggests that ethnic
differences in the IFNl3 gene may explain, at least
in part, the different response rates to therapy in
different ethnic groups. Although one study did not
ﬁnd an association with IFNl3 in the African-
Americans studied, it is likely the group (n¼53) was
underpowered to identify the association.
15
The data supporting a major role for the IFNl3
gene in clinical outcome is less clear for genotypes 2
and 3 infection than for genotype 1. The largest
study of 1362 patients by Rauch and colleagues
9
and a smaller Spanish study
14 found no association
between genotypes 2 and 3 and IFNl3 poly-
morphisms, although the treatment failure rate
in both studies was very low (37/230 patients and
9/59 patients, respectively). In contrast, two other
groups have found that IFNl3 status can predict
SVR in genotypes 2 and 3 infection, although in
one of these studies the effect was restricted to
patients who did not achieve a rapid virological
response.
13 15 Intriguingly, McCarthy and
colleagues also showed that the protective IFNl3
genotype is enriched in patients infected with
genotype 3 HCV compared with genotype 1
(p¼0.0007).
15 The mechanism behind this obser-
vation is speculative but, since the protective allele
is almost universal in Asian populations where
genotype 3 infection has evolved,
18 it seems plau-
sible that this genotype may have evolved mecha-
nisms to persist following acute infection in the
face of the protective allele.
It remains to be seen how we can best use the
information about IFNl3 in clinical practice. In
genotype 1 infection, IFNl3 is the best predictor of
treatment outcome when compared with other
known baseline predictors including ﬁbrosis score,
viral load, gender and ethnicity.
8 91 11 5However,
the sensitivity, speciﬁcity and predictive value of
the IFNl3 genetic variants currently identiﬁed are
too low to be clinically useful alone. It has been
calculated that the risk allele predicts non-response
to treatment with a sensitivity of 57% and speci-
ﬁcity of 63% with a positive predictive value of
64%.
10 For homozygotes with the protective allele,
SVR can be predicted with 65% sensitivity and 78%
speciﬁcity in patients with genotype 1.
15 It is
plausible, however, that IFNl3 alleic status will in
future be incorporated into a treatment algorithm
with other known predictors.
THE BIOLOGY OF INTERFERON LAMBDAS
The GWAS point to IFNl as a key cytokine in the
control of HCV infection. Is this biologically plau-
sible? What do we know currently about the role
and function of IFNl?
Since their discovery in 2003,
21 22 IFNls (a type
III IFN) have largely been considered a ‘poor rela-
tive’ of type I IFNs. Many functions appeared to
overlap with type I IFNs and until now there has
been little evidence of an independent and clinically
signiﬁcant role. Although the GWAS data suggest
that IFNl3 may be the type III IFN most relevant
to the pathogenesis of HCV, historically the
assessment of IFNl biology has focused on IFNl1
and IFNl2.
Classiﬁcation
IFNls are classiﬁed within the class II cytokine
family based on the similarity of their receptors.
The class II family of cytokines consists of three
types of IFNs (types I, II and III) as well as the
interleukin 10 (IL-10)-related cytokines. Type I IFNs
include IFNa and IFNb, type II IFN is IFNg and
type III IFNs consist of IFNl1, IFNl2 and IFNl3
which are also called IL29, IL28A and IL28B,
respectively. IFNl3 shares considerable amino acid
sequence homology with IFNl2 (96%) but less
with IFNl1 (81%).
21 There are currently very
limited available data comparing the different
biological activity of the three different l cytokines.
Although class II cytokines may be quite diver-
gent at the amino acid level, they are structurally
related with a shared a-helical pattern and signal
through related heterodimeric transmembrane
protein receptors. However, biological activity
ultimately depends on the receptor cytoplasmic
domains, which are not related, and these may
trigger overlapping but different biological func-
tions. This, in addition to the pattern of receptor
distribution among different cell types, means that
the different type II cytokines are functionally
distinct.
Production of IFNl
Broadly speaking, the IFNl family is similar to
IFNa in that it has both antiviral and immuno-
modulatory properties, but there are important
differences. Whereas IFNa is produced by all
nucleated cells, IFNl may be produced by fewer cell
types.
23 Plasmacytoid monocyte-derived dendritic
cells (pDC and MDDC) and macrophages produce
IFNl in response to inﬂuenza virus infection and/
or to bacterial and viral molecular mimics (the
Toll-like receptor agonists lipopolysaccharide and
poly I:C).
24 25 Interestingly, macrophage produc-
tion of IFNl is markedly enhanced by pre-culturing
these cells with IFNadevidence of interplay
between the two pathways.
26 27 There is
evidence that IFNl secretion may be inﬂuenced by
cytokinesdfor example, pDCs produce an
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Recent advances in basic scienceincreased amount of IFNl in response to IL-4
through a monocyte intermediate pathway.
25
There is also evidence that IFNl has a particular
role in skin biology, being readily produced there by
regulatory T cells and dendritic cells and acting
upon keratinocytes and melanocytes.
28 With
particular relevance to HCV infection, hepatocyte
tumour lines (HepG2 and HuH7.5),
22 27 primary
hepatocytes cultured ex vivo and liver tissue
obtained from liver biopsy specimens produce IFNl
in response to viral infection.
29 In contrast, primary
human CNS tissue does not produce IFNl.
23
IFNl receptor distribution and signalling
The IFNl receptor also has a limited cellular
distribution. IFNls signal through a heterodimeric
receptor composed of a short IL-10Rb chain (also
called IL-10R2) and a long chain IL-28Ra (also
called IL-28R1).
21 22 30 Whereas the short chain is
ubiquitously expressed and is a receptor component
of other type II-related cytokines (IL-10, IL-22,
IL-26), the long chain is unique to IFNl and has
a limited tissue distribution.
30 Hepatocytes from
liver biopsy specimens have a high IFNl receptor
expression (IL-28Ra).
23 30 31 However, this receptor
is not found on ﬁbroblasts, microvascular endo-
thelial cells, adipocytes
30 or primary CNS cells.
23 30
It is likely that the limited receptor proﬁle accounts
for the relatively restricted side effect proﬁle of
IFNl when administered to patients. Immune cells
are clearly an important target of IFNs in general,
however not all appear to express the IFNl
receptor. B cells have been shown to have the
highest level of receptors, whereas the data on T
cells are conﬂicting with both high and low
receptor levels reported.
30 31 Monocytes also appear
to have a minimal receptor expression.
30e32
All class II cytokines signal through the signal
transducers and activators of transcription (STATs)
and janus tyrosine kinases (JAK) and the biological
properties of all IFNsdespecially type I IFNs and
the IFNlsdclearly overlap. In particular, both are
produced in response to viral infection and have
antiviral properties. However, within this signalling
cascade there are subtle differences between the
IFNs that are not fully understood. All class II
cytokines appear to activate STAT1 and STAT3 and
bind to IFNg-activated sites (GAS) to various
extents in the cell nucleus, resulting in the tran-
scription of IFN-stimulated genes (ISGs). However,
in addition, type I IFNs and IFNl also activate IFN-
stimulated response elements (ISRE) through the
activation of STAT2 in association with STAT1 and
IRF9 and which again results in the production of
IFN-stimulated genes (ﬁgure 4).
33 34
Biological effects of IFNl
Microarray experiments have shown that hundreds
of ISGs are produced in response to IFN stimula-
tion. The full spectrum of genes that are stimulated
in response to different IFNs has not been deﬁned,
but it is clear that even different IFNs that bind to
the same receptor may ultimately induce different
genes
35 36 and that mutations in a single amino acid
in key locations in the IFNl binding site can have
a signiﬁcant impact on antiviral activity, altering
antiviral activity by up to 300-fold.
37 Marcello et al
evaluated ISG expression, protein production and
HCV RNA replication using the HCV replicon
system with cell culture HCV in response to IFNa
and IFNl stimulation.
38 Both cytokines ultimately
inhibited HCV replication in this system. However,
the kinetics of STAT activation and the potential
effector genes induced differed. In particular, IFNa
genes peaked and declined rapidly whereas IFNl
genes increased steadily. Thus, the functional
differences and the interplay between types I and
III IFNs are likely to lie in the ﬁne detail of this
signalling pathway, yet to be fully elucidated for
IFNl, and in the differential distribution of cells
that both produce IFNl and are able to respond to
IFNl through the presence of appropriate receptors.
The effects of IFNl, like that of IFNa,o n
immune cell function appear to be complex and
diverse. This means that in vitro studies of discrete
functions, such as the in vitro effects of IFNl on an
isolated cell type, may tell us little about the in vivo
effects in a particular disease setting where
a complex interplay of cell types and inﬂammatory
stimuli is at work. With that proviso, IFNl has
been shown to decrease the production of Th2-type
cytokines (IL-4, IL-5, IL-13, IL-14, IL-15), poten-
tially favouring a Th1 immune pathway,
39e41
increase T regulatory cells
32 and augment CD8 T
cell cytotoxicity and memory responses in
macaques vaccinated with an HIV antigen.
42
However, others have shown that immune cell
subsets (monocytes, NK, T cells) are unresponsive
to IFNl1 and IFNl2 and postulated that this is due
to the production of a soluble receptor produced by
peripheral blood mononuclear cells.
30 32 43
The antiviral effects of IFNl are clearer; in vitro
IFNl protects human cell lines against the cyto-
pathic effects of vesicular stomatis virus (VSV) and
encephalomyocarditis virus
21 22 and, in hepatocyte
models, IFNl1 inhibits both HCV and HBV repli-
cation.
31 38 44 However, some studies have shown
that, unlike IFNa, IFNl is unable to suppress HCV
completely
38 and all groups found it was less
IFNl3 and genetic technology
< SNPs are single base pair mutations and are the main sites of genetic
variation between individuals.
< SNPs linked to the IFNl3 gene predict both treatment response to PEG-IFNa/
ribavirin and spontaneous clearance of HCV.
< Individuals either heterozygous or homozygous for the risk allele are less likely
to clear HCV infection than those homozygous for the protective allele.
< African populations have a higher frequency of the risk allele than Caucasian
or East Asian populations.
< Carriers of the IFNl3 risk allele are 2e12 times more likely to fail treatment
than homozygotes for the protective allele.
< The predictive value of the IFNl3 alleles alone is insufﬁcient to determine
treatment outcome but may be a useful component of a treatment algorithm
in the future.
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Recent advances in basic sciencepotent than IFNa. The antiviral effects of IFNl on
HCV infection in patients have also been demon-
strated and are discussed further below.
45 In this
case, however, it is unclear if the antiviral effects are
mediated directly or through the stimulation of
immune cells, or both. It should be remembered
that, in the case of chronic HCV infection, the
presumed effects of IFNl on viral clearance revealed
in the GWAS are mediated through treatment with
exogenous IFNa. How then might these cytokines
interact with one another? Although IFNl may be
less potent than IFNa as a direct antiviral, together
these cytokines may have an additive effect.
27 38 46
In macrophages and hepatoma cell lines it has been
shown that IFNa upregulates IFNl1 production
1000-fold and IFNl2/3 10e100-fold.
26 27
Effect of IFNl3 polymorphism on IFNl biology
It is not yet clear howdor indeed ifdIFNl3 poly-
morphisms linked to the risk allele identiﬁed in the
GWAS affect immune function or exert speciﬁc
antiviral effects in HCV-infected patients. This will
be a difﬁcult task unless a causal IFNl3 variant is
identiﬁed, enabling the precise assessment of the
relevant IFNl3 variants in vitro. Currently, this
assessment can only be made indirectly by
observing immune function or HCV viral loads in
people with and without the risk allele that lies
a considerable distance from the IFNl3 gene. It is
currently not clear if IFNl3 production by periph-
eral blood mononuclear cells (PBMCs) is associated
with the IFNl3-linked genetic variants; while two
studies found that the protective allele is associated
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10 11
others have found it to be unrelated.
8 However,
a consistent ﬁnding appears to be that patients
with the IFNl3-linked protective allele have
a higher pretreatment HCV viral load than those
with the risk allele, with Ge and colleagues ﬁnding
that those homozygous for the protective allele had
a viral load of 6.35log10 IU/ml compared with 6.16
log10 IU/ml in those homozygous for the risk allele
(p¼1.21310
-10).
81 5This is paradoxical since
a higher pretreatment viral load has been associated
with a poor response to subsequent IFNa treat-
ment. It should be noted, however, that the pres-
ence or absence of the risk allele does not associate
with the clinically relevant viral load cut-off
(5.78log10 IU/ml)
47 48 that has been associated with
response to IFNa therapy, and it is therefore likely
that the effect of the protective allele on clinical
outcome is independent of the effect of this allele
on viral load.
IFNa and IFNl ultimately exert their functions
through the upregulation of ISGs. However, it has
been repeatedly observed that a poor response to
exogenous IFNa treatment is associated with
a higher intrahepatic ISG expression before treat-
ment.
49 50 One plausible explanation is that, in this
setting, the IFNa pathway (and thus ISG expres-
sion) is already maximally stimulated and is
therefore unresponsive to further exogenous IFNa
treatment. A recent study has shown that the
protective allele identiﬁed in the GWAS (rs8099917)
does not correlate with intrahepatic IFNl3
production.
49 Technically there are reasons why
this might be so; for example, the low levels of
IFNl3 detected in general make correlations difﬁ-
cult and by the fact that, owing to sequence
homology between IFNl3 and IFNl2, quantiﬁca-
tion by real-time PCR does not distinguish between
these cytokines. However, the protective allele does
correlate with a lower expression of ISGs and, in
those with the risk allele, lower levels of intra-
hepatic IFNl3 were associated with higher ISG
(Mx1 IFI44 and IFIT1) expression.
49 In fact, the
assessment of ISGs in response to IFNs is not
straightforward given that many hundreds of these
are expressed in liver tissue that is composed of
hepatocytes and also of immune and other cell
types. For example, in the study by Honda and
colleagues, 1359 genes were differentially expressed
between individuals with and without the protec-
tive allele. Pathway analysis suggested that IFN
action and apoptosis were upregulated in the liver
of those with the risk allele, whereas immune cell
(B, NK and dendritic cells) genes were expressed in
those with the protective allele.
49 This is supported
by the observation that ISG expression is upregu-
lated in Kupffer cells (liver macrophages) of IFNa
responders compared with non-responders,
whereas ISGs are upregulated in hepatocytes of
non-responders compared with responders.
51 In
other words, the protective effect of the IFNl3
allele may relate to the effects on or by ‘visiting’ cell
populations rather than hepatocytes themselves.
In the setting of acute HCV infection, assuming
the GWAS have correctly identiﬁed a genetic signal
linked to IFNl3, protective IFNl3 variants could
mediate viral clearance through immune stimula-
tion or direct antiviral effects through the stimu-
lation of the ‘right’ ISGs. Exactly what these ISGs
are and in which cells they are produced is not yet
clear. In the setting of chronic infection where
IFNl3 variants also appear to be associated with
response to exogenous IFNa, the protective IFNl3
variant may well be linked to a complex intra-
hepatic ISG proﬁle consisting of the ‘right’ ISGs
produced by particular cell types (ﬁgure 5).
Undoubtedly, identifying exactly what the right
ISGs are is a challenging but key question that will
be addressed in months to come.
CLINICAL STUDIES
IFNl is potentially an attractive alternative to
IFNa for the treatment of HCV infection. IFNa has
been used to treat HCV since the discovery of the
virus two decades ago. Over this time, important
modiﬁcations to IFNadsuch as the addition of
polyethylene glycol (PEG) to increase drug half-life
and the addition of ribavirin to treatment regi-
mesdhave been incorporated. Although in the
coming years HCV protease and polymerase ther-
apies will add to the anti-HCV drug armoury, the
rapid emergence of HCV variants which are resis-
tant to these new drugs means that IFNa will
probably remain an essential component of treat-
ment regimens. However, treatment with IFNa is
associated with a very signiﬁcant adverse event
proﬁle. Thrombocytopenia, neutropenia and
psychiatric complications such as anxiety, depres-
sion and sleep disturbance are particularly trou-
bling. An IFN with potent antiviral effects and
a more favourable side effect proﬁle would revolu-
tionise the treatment of HCV. In vitro experiments
have shown that that IFNl has a limited effect on
CNS and haematopoietic cells. So, with its prom-
ising antiviral activity in the liver but restricted
receptor distribution, IFNl seems like the ideal
candidate for development into a therapeutic agent.
Figure 5 Model of the possible action of interferon l (IFNl) in chronic hepatitis C virus
(HCV) infection. In chronic HCV infection, IFNa upregulates hepatic interferon-stimulated
genes (ISGs) (represented by blue circle) but this fails to clear HCV. Addition of IFNl may
result in stimulation of different ISGs (represented by green circle) and therefore HCV
clearance. The IFNl polymorphism could impact on the expression of the right hepatic
ISGs directly or through the stimulation of effector cell ISGs resulting in HCV clearance.
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was recognised before the studies that implicated
IFNl3 in particular, clinical trials to date have not
focused on IFNl3 but rather on IFNl1. Zymo-
genetics (in collaboration with Bristol-Myers
Squibb) are assessing PEG-IFNl1 in clinical studies
which, while showing promising antiviral activity,
have also uncovered a different but nevertheless
signiﬁcant side effect proﬁle from that seen with
IFNa. A phase I dose escalation study of PEG-
IFNl1 was presented in 2007 as an abstract
(http://www.zymogenetics.com/products/docum
ents/HEP_DART_PEG_IFN_12-07.pdf). Volun-
teers received a single subcutaneous injection of
PEG-IFNl1. The study was stopped after volun-
teers received 7.5 mg/kg, below the planned target
maximum of 40 mg/kg, after four volunteers
developed signiﬁcantly elevated transaminases. As
there was evidence of bioactivity at lower doses
that were not associated with hepatotoxicity,
and since peak serum concentrations at tolerated
doses were higher than those shown to have
antiviral effect in vitro,
31 38 ap h a s eIs t u d yi n
HCV-infected patients followed.
In this 4-week open-label trial, patients with
genotype-1 HCV infection received Peg-IFNl1
weekly or two-weekly.
45 The study included both
treatment-naïve patients (n¼7) and patients with
previous virological relapse with standard therapy
(n¼49). Despite the lower doses in this trial
(0.5e3 mg/kg), six patients stopped or had treat-
ment withheld due to elevated transaminase levels
and four patients had raised lipase or amylase
elevations which resolved after stopping PEG-
IFNl1. Although adverse effects were more
common in the highest dose group, it is note-
worthy that, at only 1.5 mg/kg, one patient devel-
oped severe hepatotoxicity with alanine
transaminase levels of 667 IU/ml and bilirubin
levels of 348.9 mmol/l. Furthermore, one patient
developed idiopathic thrombocytopenic purpura
and three patients developed antibodies to IFNl1
during this short treatment course. Two patients
previously treated with IFNa had cross-reactive
antibodies to IFNl at baseline (although only one
of these were neutralising antibodies), suggesting
that previous treatment with IFNa may limit IFNl
efﬁcacy in some cases.
In keeping with the in vitro data showing
a limited IFNl receptor distribution,
23 30 there was
a noticeable decrease in IFNa-type side effects.
Fatigue was the most common side effect (28.6%)
followed by nausea and myalgia (12.5% and 10.7%,
respectively). However, insomnia and inﬂuenza-like
illness were only experienced in 5.4%, well below
rates reported with IFNa and signiﬁcant neutro-
penia did not occur. This trial also showed that
IFNl1 is capable of antiviral activity in vivo. In
patients receiving a dose of $1.5 mg/kg/week, 23/
24 patients with treatment relapse achieved a fall in
viral load of $2log10 and four of these achieved
a rapid virological response, deﬁned as undetectable
viraemia at 4 weeks. Interestingly, all eight African-
American patients (a group known to respond
poorly to IFNa treatment) in this study had
a decline in viral load of >2log10 at the end of
treatment. The association of virological response
to PEG-IFNl and IFNl genotype has very recently
been assessed in an ongoing phase II study
(published in abstract form only) of PEG-IFNl1o r
PEG-IFNa with ribavirin combination therapy for
24e48 weeks, with a 2-week lead-in period of
PEG-IFNl1 or PEG-IFNa alone, in patients with
genotypes 1e4 HCV infection.
52 Interim results
from patients receiving 120e240 mg PEG-IFNl1,
revealed a 71% viral response (VR) ($2log10
reduction in viral load) at week 4 in those with
a favourable genotype compared with 25% VR in
those carrying the risk allele.
52 In this study, grade
2/3 hepatotoxicity was again observed (alanine
transaminase or aspartate aminotransferase 2.5e20
times upper limited of normal) in 20% of patients
on PEG-IFNl1 which was, however, successfully
managed with dose reduction.
52
IFNl may also in the future be considered both
in the context of cancer therapy since this cytokine
has been shown to suppress tumorigenesis in
vitro
27 31 38 and also as an immunomodulatory
agent in the suppression of Th2-associated diseases
such as allergy and atopy.
39e41 IFNl may have
a particular role in asthma since it suppresses IL-13
(known to be elevated in patients with asthma),
39
and deﬁcient IFNl production in the bronchi of
patients with asthma is associated with an increase
in respiratory infections in this population.
53
The real utility of PEG-IFNl1 in the treatment of
HCV will become more apparent following the
ﬁnal results from the ongoing phase II trial
described above which will assess both safety and
The biology of IFN lambdas
< IFNl is a type III IFN of which there are three types: IFNl1, IFNl2, IFNl3
(IL29, IL28A, IL28B).
< Plasmacytoid dendritic cells are the main producers of IFNl stimulated by
viruses and viral or bacterial mimics.
< IFNl has a restricted receptor distribution and therefore restricted targets.
< INFl has antiviral, antitumour and immunomodulatory effects.
< Upregulated hepatic ISGs pretreatment are associated with the IFNl3 risk
allele and with poor treatment outcome.
< The effect of IFNl3 on HCV clinical outcome is likely to be a complex
interplay between IFNa, the virus itself, ISGs and immunomodulation.
Clinical studies
< A phase I trial of PEG-IFNl1 has shown promising antiviral activity in both
treatment relapsers and treatment-naı ¨ve patients with HCV.
< Hepatotoxicity has been associated with the clinical use of PEG-IFNl1.
< Impaired IFNl production may lead to increased susceptibility to viral
infections.
< IFNl3 provides the opportunity to apply pharmacogenomics to HCV
treatment.
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52 Ultimately, new agents for HCV will
need to be tolerable in the setting of pre-existing
liver inﬂammation and poor hepatic reserve asso-
ciated with liver cirrhosis.
CONCLUSION
The future is likely to bring IFNl3 and this exciting
cytokine family further into the limelight, with
head-to-head clinical trials between PEG-IFNl1 and
PEG-IFNa underway for both HCV and HBV.
Importantly, although genetic studies have now
suggested that IFNl3 has a pivotal role in HCV
clinical outcome, most work to date has been with
IFNl1. IFNl3 may yet be developed as an alterna-
tive HCV treatment, particularly in those with the
risk polymorphism, and genotyping for IFNl3-
related SNPs may become part of a treatment
decision algorithm. The differential effect of IFNl
treatment on patients with and without the IL28B
polymorphism is clearly an area worth further
evaluation. Pharmacogenomic treatment
approaches are one of the future challenges of
medicine, and HCV provides the ideal opportunity
to tailor potentially toxic therapies to individuals
most likely to beneﬁt. Whether work on this
cytokine is applicable to genotypes other than 1 is
still an open question, as is establishing the ideal
therapeutic window for treatment with type III
IFNs which have demonstrated hepatotoxicity in
both healthy volunteers and patients with HCV
infection. Furthermore, elucidating the pathway by
which the IFNl3 polymorphism affects the
response to acute infection and to IFN therapies
remains an important future challenge. It is likely
that deﬁning the pattern of gene stimulation by
IFNl in different cell types, as well as potential
structural differences in IFNl3, will be critical in
solving this puzzle. In particular, investigating the
immunomodulatory effect of IFNl may well be key
to unlocking the mechanism behind both its anti-
viral effect and its toxicities. Overall, the discovery
of the link between the IFNl3 locus and HCV
disease outcome has been a huge step forward for
the ﬁeld. However, while it has provided
momentum for clinicians and basic scientists alike,
the actual route ahead still needs careful charting.
Nevertheless, while the destination is not yet clear,
the journey itself will certainly be interesting.
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